Thursday | ||||
On The Fly
|
Here's What You Missed in Cannabis This Week »
11:49 06/23/22 06/2311:49 06/23/2211:49
SNDL
Sundial Growers
Hexo
Cronos Group
Ginkgo Bioworks
Body and Mind
Australis Capital
Valens
Aurora Cannabis
CV Sciences
CannTrust
Canopy Growth
General Cannabis
Goodness Growth
Green Thumb Industries
India Globalization Capital
Tilray
Trulieve Cannabis
Zynerba
In this week's "Rising… ShowHide Related Items >><<
| |||
Recommendations
|
Zynerba price target raised to $11 from $9 at Canaccord »
07:44 06/23/22 06/2307:44 06/23/2207:44
ZYNE
Zynerba
Canaccord analyst Sumant… Canaccord analyst Sumant Kulkarni raised the firm's price target on Zynerba to $11 from $9 and keeps a Buy rating on the shares. The analyst believes the shares remain significantly undervalued if they are successful on executing its plans for Zygel, Kulkarni said based on INSPIRE data, he raised hisprobability of approval assumption for Zygel in 2022 from 15% to 33%. ShowHide Related Items >><<
|
Tuesday | ||||
Hot Stocks
|
Zynerba announces positive top line results from phase 2 trial of Zygel »
20:54 06/21/22 06/2120:54 06/21/2220:54
ZYNE
Zynerba
Zynerba "announced… Zynerba "announced positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the Company will request a meeting with the FDA to discuss the data and the regulatory path forward. The 14-week INSPIRE trial was an open-label, Phase 2 clinical trial designed to evaluate the safety, tolerability and efficacy of Zygel in children and adolescents with genetically-confirmed 22q11.2 deletion syndrome. Enrolled patients received weight-based doses of 250 mg or 500 mg daily of Zygel. Patients were allowed to increase the daily dose after six weeks of treatment to 500 mg and 750 mg if the investigator felt such increase was appropriate. One patient's dose was increased from 250 mg to 500 mg, and no patients increased to 750 mg in the treatment period. At the completion of the trial, thirteen patients entered into an extension study for up to six months." CEO Armando Anido states: "We believe the data from this Phase 2 trial are very encouraging and reinforce the potential of Zygel for the treatment of behavioral symptoms in children and adolescents with 22q, and we look forward to discussing the regulatory path forward with the FDA with these data in hand. In the near term, we will focus our resources on completing the RECONNECT trial for children and adolescents with Fragile X syndrome and progressing 22q." ShowHide Related Items >><<
|
Over a week ago | ||||
On The Fly
|
Here's What You Missed in Cannabis This Week »
11:59 06/16/22 06/1611:59 06/16/2211:59
FFLWF
Fire & Flower Holdings
High Tide
Hexo
RIV Capital
Tilray
Ayr Wellness
Innovative Industrial Properties
Valens
Aurora Cannabis
CV Sciences
CannTrust
Canopy Growth
Cronos Group
General Cannabis
Goodness Growth
Green Thumb Industries
India Globalization Capital
Trulieve Cannabis
Zynerba
In this week's "Rising… ShowHide Related Items >><<
| |||
On The Fly
|
Rising High: Exclusive talk with cannabis testing firm Green Scientific »
11:49 06/09/22 06/0911:49 06/09/2211:49
ACB
Aurora Cannabis
CV Sciences
CannTrust
Canopy Growth
Cronos Group
General Cannabis
Goodness Growth
Green Thumb Industries
India Globalization Capital
Tilray
Trulieve Cannabis
Zynerba
Atai Life Sciences
Compass Pathways
Relmada Therapeutics
In this edition of… ShowHide Related Items >><<
|
On The Fly
|
Here's What You Missed in Cannabis This Week »
11:25 06/02/22 06/0211:25 06/02/2211:25
IIPR
Innovative Industrial Properties
Flora Growth
Relmada Therapeutics
Compass Pathways
Atai Life Sciences
Zynerba
Trulieve Cannabis
Tilray
India Globalization Capital
Green Thumb Industries
Goodness Growth
General Cannabis
Cronos Group
CannTrust
CV Sciences
Aurora Cannabis
InterCure
Canopy Growth
Entourage Health
Khiron Life Sciences
In this week's "Rising… ShowHide Related Items >><<
|
Hot Stocks
| Zynerba Pharmaceuticals… Zynerba Pharmaceuticals is presenting an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting, ASCP 2022, being held May 31 - June 3, 2022. The presentation titled, "Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome," includes data demonstrating that in the ongoing long-term safety and efficacy trial of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the greatest improvement in patients with complete methylation of their FMR1 gene. Patients with complete methylation, who match the primary efficacy population in the ongoing confirmatory trial, RECONNECT, achieved and maintained clinically meaningful change in Social Avoidance, supporting one of the key design enhancements for RECONNECT. Zygel was well-tolerated with long-term administration with up to 38 months of exposure. The poster titled, "RECONNECT: Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX Completed During SARS-COV-2 Pandemic," describes how learnings from CONNECT-FX, the first randomized, double-blind, placebo-controlled trial of Zygel in the treatment of FXS, shaped the design of RECONNECT. In addition to the primary endpoint of the RECONNECT trial being measured in patients who have a completely methylated FMR1 gene, the treatment period of the trial has been extended by four weeks and an additional weight-based dose has been added for participants weighing greater than 50kg. ShowHide Related Items >><<
|
Over a month ago | ||||
On The Fly
|
Rising High: Exclusive talk with cannabis company Tyson 2.0 »
11:42 05/26/22 05/2611:42 05/26/2211:42
CMPS
Compass Pathways
Atai Life Sciences
Relmada Therapeutics
Zynerba
Trulieve Cannabis
Tilray
India Globalization Capital
Green Thumb Industries
Goodness Growth
General Cannabis
Cronos Group
Canopy Growth
CannTrust
CV Sciences
Aurora Cannabis
Columbia Care
In this edition of… ShowHide Related Items >><<
| |||
On The Fly
|
Rising High: Exclusive talk with biotech company Tryp Therapeutics »
11:59 05/19/22 05/1911:59 05/19/2211:59
GDNSF
Goodness Growth
Zynerba
Trulieve Cannabis
Tilray
India Globalization Capital
Green Thumb Industries
General Cannabis
Cronos Group
Canopy Growth
CannTrust
CV Sciences
Aurora Cannabis
Relmada Therapeutics
Compass Pathways
Atai Life Sciences
Tryp Therapeutics
In this edition of… ShowHide Related Items >><<
| |||
Syndicate
| ShowHide Related Items >><<
|